This study investigated the impact of pretransplant cytomegalovirus (CMV) serostatus and posttransplant CMV reactivation and disease on umbilical cord blood transplant (UCBT) outcomes. Between 1994 and 2007, 332 patients with hematologic malignancies underwent UCBT and 54% were CMV seropositive. Pretransplant recipient CMV serostatus had no impact on acute or chronic graft-versus-host disease (aGVHD, cGVHD), relapse, disease-free survival (DFS), or overall survival (OS). There was a trend toward greater day 100 treatment-related mortality (TRM) in CMV-seropositive recipients (P = .07). CMV reactivation occurred in 51% (92/180) of patients with no difference in myeloablative (MA) versus reduced-intensity conditioning (RIC) recipients (P = .33). Similarly, reactivation was not influenced by the number of UCB units transplanted, the degree of HLA disparity, the CD34+ or CD3+ cell dose, or donor killer cell immunoglobulin-like receptor (KIR) gene haplotype. Rapid lymphocyte recovery was associated with CMV reactivation (P = .02). CMV reactivation was not associated with aGVHD (P = .97) or cGVHD (P = .65), nor did it impact TRM (P = .88), relapse (P = .62), or survival (P = .78). CMV disease occurred in 13.8% of the CMV-seropositive patients, resulting in higher TRM (P = .01) and lower OS (P = .02). Thus, although recipient CMV serostatus and CMV reactivation have little demonstrable impact on UCB transplant outcomes, the development of CMV disease remains a risk, associated with inferior outcomes.
Bibliographical noteFunding Information:
Financial disclosure: This work was supported by the American Cancer Society (MRV) , Children's Cancer Research Fund (J.C.B., M.R.V., and J.E.W.), P01 CA65493 (J.S.M. and J.E.W.), and P01 111412 (M.R.V., S.C., and J.S.M.).
- Cord blood transplantation